ABL1 and acute myeloid leukemia: Another drug, AT9283, a small molecule inhibitor of Aurora kinases A and B, c-ABL, JAK2 and other kinases, caused HTN as dose-limiting toxicity when used in the treatment of refractory AML and advanced PMF/SMF [84].